<!DOCTYPE html>
<html class="has-navbar-fixed-top">

<head>
  <title>
    FinanClub
</title>
<meta name="viewport" content="width=device-width">
<meta name="title" content="finan.club">
<meta name="description" content="finan.club offers the us stock analysis by ChatGPT ">
<meta name="keywords" content="Stocks Analysis,ChatGPT Trading,AI Analyst">
<meta name="robots" content="index, follow">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="language" content="English">
<link rel="stylesheet" href="https://jenil.github.io/bulmaswatch/darkly/bulmaswatch.min.css">
<link href="https://unpkg.com/@fortawesome/fontawesome-free@5.13.0/css/all.css" rel="stylesheet">
<link rel="stylesheet" href="/css/style.css">
<title>
  FinanClub
  </title>
  <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-7398757278741889"
  crossorigin="anonymous"></script>
</head>

<body class="theme-body">
  <nav class="navbar is-dark is-fixed-top">
  <div class="container">
  <div class="navbar-brand">
    <a class="navbar-item" href="/">
      <img src="/logo.png" width="112" height="28">
    </a>
    <a class="navbar-item" href="https://github.com/etrobot/hugo-theme-financlub" target="_blank">
      <i class="fab fa-github"></i>
    </a>
    <a class="navbar-item" href="https://twitter.com/etrobot" target="_blank">
      <i class="fab fa-twitter"></i>
    </a>
  </div>
</div>
</nav>
  <div class="container theme-padding-mobile">
    <section class="columns is-multiline">
      <main class="column">
        
<div class="block">
  <h1 class="title">IBRX <span class="subtitle is-4" > Stock Analysis by ChatGPT</span></h1> 
    <h3 class="subtitle">
      <p class="subtitle is-6"><a href="/author/friday-wall">Friday Wall</a> Dec 18, 2023</p>
    </h3>
    <article class="content">
      <p>score:697</p>
<h3 id="chances">Chances:</h3>
<ol>
<li>ImmunityBio&rsquo;s resubmission of its Biologics License Application for N-803 has been accepted for review by the FDA, indicating potential for approval of a promising treatment for bladder cancer.</li>
<li>New data shows that ImmunityBio&rsquo;s Memory Cytokine-Enriched Natural Killer cells may provide benefit to patients with small cell lung cancer and other types of neuroendocrine tumors, offering a positive outlook for the company&rsquo;s therapies.</li>
<li>Successful financing transactions have resulted in approximately $200 million in proceeds for ImmunityBio, providing the company with significant funding for future growth and development.</li>
<li>Participation in the 35th Annual Piper Sandler Healthcare Conference offers ImmunityBio an opportunity to showcase its advancements in immunotherapy and attract investor attention.</li>
<li>The appointment of Enrique Diloné, Ph.D., as Chief Technology Officer demonstrates ImmunityBio&rsquo;s focus on strengthening its global manufacturing capabilities in preparation for potential FDA approval of key treatments.</li>
</ol>
<h3 id="risks">Risks:</h3>
<ol>
<li>The success of ImmunityBio&rsquo;s therapies is contingent on FDA approval, and there is always a risk of regulatory challenges or delays in the approval process.</li>
<li>The company&rsquo;s performance and stock value may be affected by market volatility, competition in the immunotherapy industry, and uncertainties surrounding clinical trial results.</li>
</ol>
<h3 id="score697">Score:697</h3>
<p>chances characters count - risks characters count = -303</p>
<p>investment score = 1000 + chances characters count - risks characters count

<div class="tradingview-widget-container">
  <div id="tradingview_7c694"></div>
  <script type="text/javascript" src="https://s3.tradingview.com/tv.js"></script>
  <script type="text/javascript">
  new TradingView.widget(
  {
  "autosize": true,
  "symbol": "Nasdaq:IBRX",
  "interval": "M",
  "timezone": "Etc/UTC",
  "theme": "dark",
  "style": "1",
  "locale": "en",
  "enable_publishing": false,
  "allow_symbol_change": true,
  "hide_side_toolbar": true,
  "studies": [
    "STD;MA%1Cross"
  ],
  "container_id": "tradingview_7c694"
}
  );
  </script>
</div>
</p>
<h3 id="references">References:</h3>
<ul>
<li>2023-11-16 <a href="https://finance.yahoo.com/news/immunitybio-participate-35th-annual-piper-140000137.html">ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference</a></li>
<li>2023-11-07 <a href="https://finance.yahoo.com/news/first-data-immunitybio-memory-cytokine-140000492.html">First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity</a></li>
<li>2023-10-26 <a href="https://finance.yahoo.com/news/fda-accepts-immunitybio-bla-resubmission-130000546.html">FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date</a></li>
<li>2023-10-23 <a href="https://finance.yahoo.com/news/immunitybio-announces-biological-license-application-130000888.html">ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ</a></li>
<li>2023-09-11 <a href="https://finance.yahoo.com/news/immunitybio-announces-470-million-equity-100000603.html">ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities</a></li>
<li>2023-09-08 <a href="https://finance.yahoo.com/news/immunitybio-inc-nasdaq-ibrx-top-145550154.html">ImmunityBio, Inc. (NASDAQ:IBRX) Top Key Executive Patrick Soon-Shiong&rsquo;s holdings dropped 14% in value as a result of the recent pullback</a></li>
<li>2023-08-03 <a href="https://finance.yahoo.com/news/immunitybio-names-enrique-dilon-chief-130000568.html">ImmunityBio Names Enrique Diloné as Chief Technology Officer</a></li>
<li>2023-07-21 <a href="https://finance.yahoo.com/news/immunitybio-announces-execution-40-million-003200481.html">ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors</a></li>
<li>2023-07-10 <a href="https://finance.yahoo.com/news/phase-1-study-indicates-allogeneic-133000260.html">Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients</a></li>
<li>2023-05-22 <a href="https://finance.yahoo.com/news/immunitybio-participate-jefferies-global-healthcare-130000958.html">ImmunityBio to Participate in the Jefferies Global Healthcare Conference</a></li>
</ul>

    </article>
    <div class="block">
        
        <span class="subtitle is-6 m-1">Previous Post: <a class="link" href="https://finan.club/us/on/">ON</a></span>
        
        
        <span class="subtitle is-6 m-1">Next Post: <a class="link" href="https://finan.club/us/aeo/">AEO</a></span>
        
    </div>
</div>

      </main>
      <aside class="column is-one-quarter is-full-mobile">
    
    
    <div class="block">
        <div class="block"><a class="subtitle is-6" href="/author">Authors</a></div>
        <div class="tags">
            
            <div class="tag">
                <a href="/author/friday-wall">friday-wall (55)</a>
            </div>
            
        </div>
            
    <ins class="adsbygoogle"
    style="display:block"
    data-ad-client="ca-pub-7398757278741889"
    data-ad-slot="7456114770"
    data-ad-format="auto"
    data-full-width-responsive="true"></ins>
        <div class="block"><a class="subtitle is-6" href="/tags">Tags</a></div>
        <div class="tags">
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
                
            
        </div>
    </div>
    <script>
        (adsbygoogle = window.adsbygoogle || []).push({});
    </script>
</aside>
    </section>
  </div>
  <footer class="footer">
  <div class="content has-text-centered">
    <p>
      © 2023 Frank Lin
    </p>
  </div>
</footer>
</body>

</html>